- Home
- MURA vs BRNS Comparison
MURA vs BRNS Comparison
Compare MURA & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- BRNS
- Stock Information
- Founded
- MURA 2013
- BRNS 2016
- Country
- MURA Ireland
- BRNS United Kingdom
- Employees
- MURA N/A
- BRNS N/A
- Industry
- MURA
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- BRNS Health Care
- Exchange
- MURA Nasdaq
- BRNS Nasdaq
- Market Cap
- MURA 45.8M
- BRNS 38.7M
- IPO Year
- MURA N/A
- BRNS 2021
- Fundamental
- Price
- MURA $2.64
- BRNS $1.07
- Analyst Decision
- MURA Strong Buy
- BRNS Strong Buy
- Analyst Count
- MURA 4
- BRNS 2
- Target Price
- MURA $13.00
- BRNS $3.00
- AVG Volume (30 Days)
- MURA 190.3K
- BRNS 51.1K
- Earning Date
- MURA 05-14-2025
- BRNS 05-07-2025
- Dividend Yield
- MURA N/A
- BRNS N/A
- EPS Growth
- MURA N/A
- BRNS N/A
- EPS
- MURA N/A
- BRNS N/A
- Revenue
- MURA N/A
- BRNS $14,969,000.00
- Revenue This Year
- MURA $34.35
- BRNS N/A
- Revenue Next Year
- MURA N/A
- BRNS N/A
- P/E Ratio
- MURA N/A
- BRNS N/A
- Revenue Growth
- MURA N/A
- BRNS 4381.74
- 52 Week Low
- MURA $0.95
- BRNS $0.64
- 52 Week High
- MURA $4.74
- BRNS $2.14
- Technical
- Relative Strength Index (RSI)
- MURA 51.80
- BRNS 59.44
- Support Level
- MURA $2.56
- BRNS $0.65
- Resistance Level
- MURA $2.72
- BRNS $1.11
- Average True Range (ATR)
- MURA 0.14
- BRNS 0.12
- MACD
- MURA -0.02
- BRNS 0.02
- Stochastic Oscillator
- MURA 33.33
- BRNS 91.23
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.